Abstract
Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have